Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T07816
|
|||||
Target Name |
Leishmania major Proteasome (Leishm Proteasome)
|
|||||
Gene Name |
NOUNIPROTAC
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Leishmaniasis [ICD-11: 1F54] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | LXE408 | Drug Info | Phase 2 | Visceral leishmaniasis | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | LXE408 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. J Med Chem. 2020 Oct 8;63(19):10773-10781. | |||||
REF 2 | Clinical pipeline report, company report or official report of Novartis. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.